FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bernd Lathan

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
JU Rüffer; Henning Flechtner; P Tralls; Andreas Josting; Markus Sieber; Bernd Lathan; Volker Diehl
Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG).
Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Markus Loeffler
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Markus Sieber; Hans Tesch; Beate Pfistner; Ulrich Rueffer; Bernd Lathan; Oana Brosteanu; Ursula Paulus; Tina Koch; Michael Pfreundschuh; Markus Loeffler; Andreas Engert; Andreas Josting; Jürgen Wolf; Dirk Hasenclever; Jeremy Franklin; Eckhart Duehmke; Axel Georgii; Klaus-Peter Schalk; Hartmut Kirchner; Gottfried Doelken; Reinhold Munker; Peter Koch; Richard Herrmann; richard greil; Anna Paola Anselmo; Volker Diehl
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bernd Lathan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: JU Rüffer; Henning Flechtner; P Tralls; Andreas Josting; Markus Sieber; Bernd Lathan; Volker Diehl
Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG).
European journal of cancer (Oxford, England : 1990) 2003;39(15):2179-86.
2003: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Markus Loeffler
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
The New England journal of medicine 2003;348(24):2386-95.
2002: Markus Sieber; Hans Tesch; Beate Pfistner; Ulrich Rueffer; Bernd Lathan; Oana Brosteanu; Ursula Paulus; Tina Koch; Michael Pfreundschuh; Markus Loeffler; Andreas Engert; Andreas Josting; Jürgen Wolf; Dirk Hasenclever; Jeremy Franklin; Eckhart Duehmke; Axel Georgii; Klaus-Peter Schalk; Hartmut Kirchner; Gottfried Doelken; Reinhold Munker; Peter Koch; Richard Herrmann; richard greil; Anna Paola Anselmo; Volker Diehl
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):476-84.
2001: Ulrich Rueffer; Kai Breuer; Andreas Josting; Bernd Lathan; Markus Sieber; Oliver Manzke; FJ Grotenhermen; Hans Tesch; Henning Bredenfeld; Peter Koch; Hiltrud Nisters-Backes; Jürgen Wolf; Andreas Engert; Volker Diehl
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1307-11.
2001: Eckhart Dühmke; Jeremy Franklin; Michael Pfreundschuh; Susanne Sehlen; Normann Willich; Ursula Rühl; Rolf-Peter Müller; P Lukas; A Atzinger; Ursula Paulus; Bernd Lathan; U Rüffer; Markus Sieber; Jürgen Wolf; Andreas Engert; Axel Georgii; Susanne Staar; Richard Herrmann; M Beykirch; Hartmut Kirchner; A Emminger; richard greil; E Fritsch; Peter Koch; A Drochtert; Oana Brosteanu; Dirk Hasenclever; Markus Loeffler; Volker Diehl
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2905-14.
2001: Michael Pfreundschuh; Dirk Hasenclever; Markus Loeffler; G Ehninger; Norbert Schmitz; Hartmut Kirchner; Peter Koch; Bernd Lathan; Ulrich Rueffer; Michael Sextro; Jeremy Franklin; Hans Tesch; Volker Diehl
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):471-7.
1999: Peter Staib; Bernd Lathan; Timo Schinköthe; S Wiedenmann; B Pantke; T Dimski; Dimitris Voliotis; Volker Diehl
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Advances in experimental medicine and biology 1999;457():437-44.
1998: Hans Tesch; Volker Diehl; Bernd Lathan; Dirk Hasenclever; Markus Sieber; U Rüffer; Andreas Engert; Jeremy Franklin; Michael Pfreundschuh; K P Schalk; G Schwieder; G Wulf; Gottfried Dölken; P Worst; Peter Koch; Norbert Schmitz; U Bruntsch; C Tirier; U Müller; Markus Loeffler
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Blood 1998;92(12):4560-7.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; J U Rueffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; E Duehmke; Axel Georgii; Markus Loeffler
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3810-21.
1998: Peter Staib; Bernd Lathan; S Knöppel-Schwark; Hans Tesch; Dimitris Voliotis; H T Steinmetz; Martin Schwonzen; PD Wickramanayake; Volker Diehl
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):221-3.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; JU Rüffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; Eckhart Dühmke; Axel Georgii; Markus Loeffler
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S67-71.
1997: Volker Diehl; Markus Sieber; U Rüffer; Bernd Lathan; Dirk Hasenclever; Michael Pfreundschuh; Markus Loeffler; D Lieberz; Peter Koch; M Adler; Hans Tesch
BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):143-8.
1997: Andreas Engert; Roland Schnell; Frithjof C Küpper; Marcel Reiser; M Engelhard; M Wilhelm; Bernd Lathan; S Baltes-Engler; B Winterhalter; M E Scheulen; B Dederichs; Hans Tesch; B Wörmann; Volker Diehl
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;24(5-6):513-22.
1994: Andreas Engert; Roland Schnell; Bernd Lathan; Volker Diehl
[Limits and value of chemotherapy in elderly patients].
Medizinische Klinik (Munich, Germany : 1983) 1994;89(11):603-10.
1994: Michael Pfreundschuh; U Rueffer; Bernd Lathan; Norbert Schmitz; O Brosteanu; Dirk Hasenclever; R Haas; H Kirchner; Peter Koch; R Kuse
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):580-6.
1993: Bernd Lathan; Michael Pfreundschuh; Volker Diehl
[Therapeutic strategies of Hodgkin's disease].
Der Internist 1993;34(2):146-54.
1993: Wolfgang Hiddemann; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; K Becker; Leopold Balleisen; Bernd Lathan
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Leukemia & lymphoma 1993;10 Suppl():133-7.
1992: Thomas Büchner; Wolfgang Hiddemann; U W Schaefer; Helmut Löffler; Georg Maschmeyer; Wolf-Dieter Ludwig; Carlo Aul; Bernd Lathan; Achim Heinecke
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.
Leukemia 1992;6 Suppl 4():68-70.
1992: Michael Pfreundschuh; Bernd Lathan; Markus Loeffler; U Rüffer; Dirk Hasenclever; Volker Diehl
The Second International Symposium on Hodgkin's Disease. Workshop III: Recommendations for future clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():101-4.
1992: M Schwonzen; Michael Pfreundschuh; C Pohl; A Schuh; Bernd Lathan; V Diehl
Binding of monoclonal anti-interleukin 2 antibody to nucleoli in acute leukemia blast cells.
Leukemia research 1992;16(6-7):589-95.
1992: Angela Gause; G Schmitz; A K von Kalle; Bernd Lathan; Volker Diehl; Michael Pfreundschuh
The clinical relevance of IgG subclasses in acute leukemias: low serum IgG as a risk factor for early death due to infection in acute myelogenous leukemia.
Leukemia research 1992;16(2):165-71.
1991: A Kux; Klaus Wassermann; R K Klocke; Bernd Lathan; G Pothoff; G Mager; Gerhard R F Krueger; K F Neufang; H H Hilger
[Bronchial carcinoma or Wegener's disease: problems with differential diagnosis and an atypical course].
Medizinische Klinik (Munich, Germany : 1983) 1991;86(8):414-8.
1991: Hans Tesch; Bernd Lathan; Volker Diehl
[Malignant lymphomas in HIV infected patients].
Der Internist 1991;32(8):495-8.
1991: Wolfgang Hiddemann; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; K Becker; Leopold Balleisen; Bernd Lathan
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Seminars in hematology 1991;28(3 Suppl 4):35-8.
1990: Bernd Lathan; K Kerkhoff; W Scheithauer; Volker Diehl
In vitro drug sensitivity testing with agar-containing glass capillaries.
Anticancer research 1990;10(4):1075-8.
1990: Wolfgang Hiddemann; H C Aul; Georg Maschmeyer; D Urbanitz; Bernd Lathan; A Reichle; H Köppler; R Donhuijsen-Ant; Wolf-Dieter Ludwig; T Grüneisen
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Haematology and blood transfusion 1990;33():604-10.
1990: Bernd Lathan; M von Tettau; K Verpoort; V Diehl
Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis.
Haematology and blood transfusion 1990;33():295-8.
1989: Bernd Lathan; K Kerkhoff; W Scheithauer; Daniel Von Hoff; Volker Diehl
Homogeneous growth of tumor cell colonies in agar containing glass capillaries.
Anticancer research 1989;9(6):1897-902.
1989: Wolfgang Hiddemann; Carlo Aul; Georg Maschmeyer; Bernd Lathan; H Köppler; R Hoffmann; T Grüneisen; R Donhuijsen-Ant; Wolf-Dieter Ludwig; Leopold Balleisen
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results.
Onkologie 1989;12(1):4-6.
1989: Bernd Lathan; Daniel Von Hoff; G M Clark; E E Elslager
Evaluation of an amsacrine analog in a human tumor cloning system.
Cancer chemotherapy and pharmacology 1989;24(4):230-2.
1988: Bernd Lathan; V Diehl; G M Clark; Daniel Von Hoff
Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
European journal of cancer & clinical oncology 1988;24(12):1891-5.